Pulmonary Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Hypertension.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-06-09EMA Authorised: Winrevair (sotatercept) — Merck Sharp & Dohme B.V.
EMA authorised Winrevair (sotatercept) from Merck Sharp & Dohme B.V. for pulmonary hypertension and related hypertension therapeutic area.
-
EMA approval · 2026-01-29EMA Authorised: INOmax (nitric oxide) — Linde Healthcare AB
The EMA authorized INOmax (nitric oxide) for pulmonary hypertension and respiratory insufficiency. The marketing authorization holder is Lin…
-
EMA approval · 2025-12-19EMA Authorised: Macitentan AccordPharma (macitentan) — Accord Healthcare
The EMA authorised Macitentan AccordPharma (macitentan) for the treatment of pulmonary hypertension, including pulmonary arterial hypertensi…
-
EMA approval · 2023-04-11EMA Authorised: Granpidam (sildenafil citrate) — Accord Healthcare S.L.U.
Granpidam (sildenafil citrate) has been authorised in the EU for use in hypertension and pulmonary hypertension with Accord Healthcare S.L.U…
-
FDA approval · 2019-02-13FDA Approved: INOMAX — Supplemental Application (INO Therapeutics LLC)
The FDA approved a supplemental application for INOMAX (nitric oxide) submitted by INO Therapeutics LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.